Loading drug development pipeline…
Loading drug development pipeline…
Derived
For each drug, the most advanced stage supported by registered interventional trials and jurisdiction-aware approval records. Approval in any ingested jurisdiction outranks trial phase; a drug is counted once, at its highest stage.
Computedci-drug-pipeline-v1Stage rulesApprovals feed →
Funnel
Drugs reach Malignant Nasopharyngeal Neoplasm through trial conditions or approval indications mapped to it or to one of its descendant entities.
28 drugs · 154 active trials
1 drug · 6 active trials
1 drug · 21 active trials
Outside the funnel: Phase not stated 1. "Withdrawn" = every approval record for the scope is withdrawn or superseded; "phase not stated" = trials exist but none states a phase.
Data updated 17 hours agoSource updated unknownrecomputed with the intelligence layer
Drugs
Most advanced stage first, then most active trials. Trial counts are interventional studies linking the drug (and, when a cancer is selected, the cancer).
| Drug | Stage | Max phase | Active | Recruiting | Phase 3 | Total trials | Approvals | Jurisdictions | First approval | First trial |
|---|---|---|---|---|---|---|---|---|---|---|
| Toripalimab | Approved | Phase 3 | 21 | 13 | 6 | 25 | 1 | US | Oct 27, 2023 | Jun 28, 2020 |
| Nimotuzumab | Phase 4 | Phase 4 | 6 | 6 | 4 | 13 | 0 | — | — | 2009-10 |
| Cisplatin | Phase 3 | Phase 3 | 45 | 21 | 49 | 100 | 0 | — | — | Apr 1, 1998 |
| Gemcitabine | Phase 3 | Phase 3 | 30 | 13 | 20 | 47 | 0 | — | — | 2006-06 |
| Capecitabine | Phase 3 | Phase 3 | 14 | 4 | 15 | 24 | 0 | — | — | 2004-11 |
| Nivolumab | Phase 3 | Phase 3 | 8 | 4 | 1 | 13 | 0 | — | — | Jul 21, 2015 |
| Chemotherapy | Phase 3 | Phase 3 | 8 | 4 | 7 | 12 | 0 | — | — | 2016-12 |
| Camrelizumab | Phase 3 | Phase 3 | 5 | 3 | 5 | 16 | 0 | — | — | Apr 26, 2017 |
| Docetaxel | Phase 3 | Phase 3 | 5 | 1 | 9 | 16 | 0 | — | — | Dec 10, 2008 |
| Fluorouracil | Phase 3 | Phase 3 | 5 | 1 | 6 | 16 | 0 | — | — | Apr 1, 1998 |
| Tislelizumab | Phase 3 | Phase 3 | 5 | 0 | 2 | 8 | 0 | — | — | Apr 15, 2019 |
| Sintilimab | Phase 3 | Phase 3 | 5 | 1 | 2 | 7 | 0 | — | — | Jun 1, 2020 |
| Bevacizumab | Phase 3 | Phase 3 | 3 | 0 | 1 | 8 | 0 | — | — | 2001-07 |
| Paclitaxel | Phase 3 | Phase 3 | 3 | 0 | 1 | 4 | 0 | — | — | 2008-03 |
| Adebrelimab | Phase 3 | Phase 3 | 3 | 2 | 1 | 3 | 0 | — | — | Jun 18, 2024 |
| Cetuximab | Phase 3 | Phase 3 | 2 | 1 | 2 | 14 | 0 | — | — | 2005-01 |
| Carboplatin | Phase 3 | Phase 3 | 2 | 1 | 3 | 7 | 0 | — | — | 2008-01 |
| Nab-paclitaxel | Phase 3 | Phase 3 | 2 | 1 | 1 | 5 | 0 | — | — | Jul 9, 2019 |
| Atezolizumab | Phase 3 | Phase 3 | 2 | 0 | 1 | 2 | 0 | — | — | Mar 3, 2017 |
| Serplulimab | Phase 3 | Phase 3 | 2 | 1 | 1 | 2 | 0 | — | — | Dec 14, 2022 |
| Nedaplatin | Phase 3 | Phase 3 | 1 | 1 | 5 | 8 | 0 | — | — | 2011-01 |
| Dexamethasone | Phase 3 | Phase 3 | 1 | 1 | 2 | 5 | 0 | — | — | 2009-11 |
| Asparaginase | Phase 3 | Phase 3 | 1 | 0 | 1 | 2 | 0 | — | — | Apr 1, 2023 |
| Immune Checkpoint Inhibitor | Phase 3 | Phase 3 | 1 | 1 | 1 | 1 | 0 | — | — | Jan 10, 2024 |
| Radiation Therapy | Phase 3 | Phase 3 | 1 | 1 | 1 | 1 | 0 | — | — | Jan 1, 2022 |
| Ifosfamide | Phase 3 | Phase 3 | 0 | 0 | 1 | 2 | 0 | — | — | Apr 15, 2004 |
| Adjuvant Chemotherapy | Phase 3 | Phase 3 | 0 | 0 | 1 | 1 | 0 | — | — | Sep 4, 2006 |
| Celecoxib | Phase 3 | Phase 3 | 0 | 0 | 1 | 1 | 0 | — | — | 2014-01 |
| Etoposide | Phase 3 | Phase 3 | 0 | 0 | 1 | 1 | 0 | — | — | 2014-06 |
| Leucovorin | Phase 3 | Phase 3 | 0 | 0 | 1 | 1 | 0 | — | — | 2015-05 |
| Pembrolizumab | Phase 2 | Phase 2 | 7 | 2 | 0 | 15 | 0 | — | — | Oct 8, 2015 |
| Ipilimumab | Phase 2 | Phase 2 | 3 | 0 | 0 | 5 | 0 | — | — | Jan 30, 2017 |
| Cemiplimab | Phase 2 | Phase 2 | 2 | 1 | 0 | 2 | 0 | — | — | May 27, 2026 |
| Cyclophosphamide | Phase 2 | Phase 2 | 1 | 0 | 0 | 5 | 0 | — | — | 2008-01 |
| Fludarabine | Phase 2 | Phase 2 | 1 | 0 | 0 | 4 | 0 | — | — | 2015-02 |
| Cabozantinib | Phase 2 | Phase 2 | 1 | 0 | 0 | 2 | 0 | — | — | Aug 11, 2022 |
| Vorinostat | Phase 2 | Phase 2 | 1 | 0 | 0 | 2 | 0 | — | — | Mar 3, 2006 |
| Interferon Beta-1a | Phase 2 | Phase 2 | 1 | 1 | 0 | 1 | 0 | — | — | Jan 10, 2023 |
| Palbociclib | Phase 2 | Phase 2 | 1 | 0 | 0 | 1 | 0 | — | — | 2022-06 |
| Pemetrexed | Phase 2 | Phase 2 | 1 | 1 | 0 | 1 | 0 | — | — | Jun 25, 2024 |
| Erlotinib Hydrochloride | Phase 2 | Phase 2 | 0 | 0 | 0 | 3 | 0 | — | — | 2001-12 |
| Oxaliplatin | Phase 2 | Phase 2 | 0 | 0 | 0 | 3 | 0 | — | — | 2004-10 |
| Bortezomib | Phase 2 | Phase 2 | 0 | 0 | 0 | 2 | 0 | — | — | 2006-08 |
| Durvalumab | Phase 2 | Phase 2 | 0 | 0 | 0 | 2 | 0 | — | — | Jun 1, 2020 |
| Icotinib | Phase 2 | Phase 2 | 0 | 0 | 0 | 2 | 0 | — | — | 2012-02 |
| Paclitaxel Liposome | Phase 2 | Phase 2 | 0 | 0 | 0 | 2 | 0 | — | — | Nov 14, 2016 |
| Akt Inhibitor MK2206 | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | 2011-07 |
| Aldesleukin | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | Apr 7, 2017 |
| Aspirin | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | Jan 1, 2018 |
| Avelumab | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | 2017-01 |
Stages describe registered activity and ingested regulatory records, not efficacy. Only ingested jurisdictions (currently US and Canada) can place a drug at "approved"; trial phases are as registered by sponsors. Nothing here is a treatment recommendation.